Global Checkpoint Inhibitors for Treating Cancer Sales Market Report 2018

This report studies the global Checkpoint Inhibitors for Treating Cancer market status and forecast, categorizes the global Checkpoint Inhibitors for Treating Cancer market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).

Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.

Request Sample Copy of the Report @ https://www.qyresearch.com/sample-form/form/162636/global-checkpoint-inhibitors-for-treating-cancer-sales-market

Those four kinds of checkpoint inhibitors are mainly used to treat melanoma, bladder cancer and others. In 2015, melanoma treatment consumed checkpoint inhibitors took a share of 80.53%. In 2016, melanoma treatment consumed checkpoint inhibitors will be 68153g. Bladder cancer treatment consumed checkpoint inhibitors will be 1978g.

Although YERVOY® (ipilimumab), OPDIVO® (nivolumab), KEYTRUDA® (pembrolizumab) and Tecentriq® (atezolizumab) are four indispensable medicines for cancer treatment, they also has many shortages. Firstly, they all have side effect for patient. Secondly, price of checkpoint inhibitors for treating cancer is too expensive. CTLA-4 inhibitors price is about 118.2 USD/mg in 2016. PD-1 inhibitors price is about 28.6 USD/mg in 2016. PD-L1 inhibitors price is about 30.5 USD/mg in 2016. For most patients, the price is unbearable.

The global Checkpoint Inhibitors for Treating Cancer market is valued at 4690 million US$ in 2017 and will reach 29000 million US$ by the end of 2025, growing at a CAGR of 25.6% during 2018-2025.

Ask for Discount on Research Report@ https://www.qyresearch.com/request-discount/form/162636/global-checkpoint-inhibitors-for-treating-cancer-sales-market

The major players covered in this report

•     Bristol-Myers Squibb(BMS)
•     Merck
•     Roche

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering

•     United States
•     Europe
•     China
•     Japan
•     Southeast Asia
•     India

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

•     PD-1 Inhibitors
•     PD-L1 Inhibitors
•     CTLA-4 Inhibitors

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

•     Melanoma Treatment
•     Bladder Cancer Treatment
•     Other

Click to view the full report TOC, figure and tables:https://www.qyresearch.com/index/detail/162636/global-checkpoint-inhibitors-for-treating-cancer-sales-market